Protalix BioTherapeutics, Inc. (PLX) dividend history

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3050% below fair value

$3.05+0.09 (+3.04%)

Close on Nov 13, 2026Market cap $245.74MP/E 12.2Yield –

Dividends

No dividend per share appears in Protalix BioTherapeutics's annual filings since fiscal 2010.

Parsed from the XBRL in Protalix BioTherapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 20, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PLX.

Revenue growth37.0% · median 133.8%

Gross margin71.2% · median 29.2%

Operating margin29.8% · median -311.0%

Net margin24.3% · median -275.2%

Advertisement
300 × 250

See a number that looks wrong?